The P300 component of evoked potentials in the evaluation of schizophrenia: New evidence and visions of the future;El componente P300 de los potenciales evocados en la valoración de la esquizofrenia: Nuevas evidencias y visiones de futuro

Revista de Neurologia

Volumn 32, Issue 3, 2001, Pages 250-258

  Martin Loeches M ^a   Munoz F ^a   Hinojosa, J A ^a   Molina, V ^a   Pozo, M A ^a  

^a INSTITUTO PLURIDISCIPLINAR   (Spain)

Author keywords

Biological marker; Cognitive potentials; Evoked potentials; Neurodegeneration; P300 component; Schizophrenia; Vulnerability

Indexed keywords

NEUROLEPTIC AGENT;

ATTENTION; CLINICAL FEATURE; COGNITION; DISEASE MARKER; EVOKED RESPONSE; GENETIC RISK; MEMORY; NERVE DEGENERATION; NEUROPSYCHOLOGY; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; VALIDATION PROCESS;

EID: 0035245105     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3203.2000397     Document Type: Review

References (69)

1. The recording and analysis of event-related potentials
2. Evoked-potentials correlates of stimulus uncertainty
3. Generators of the late cognitive potentials in auditory and visual oddball tasks
4. Some features of the auditory event-related response in schizophrenia
5. A continuous-performance test of brain damage
6. P300 subcomponent abnormalities in schizophrenia: III. Deficits in unaffected siblings of schizophrenic probands
7. Cognitive psychophysiology and human information processing
8. Schizophrenia: The broken P300 and beyond
9. Effects of stimulus repetition, duration, and rise time on startle blink and automatically elicited P300
10. Is the P300 component a manifestation of context updating? (Commentary on Verleger's critique of the context updating model)
11. On the dependence of P300 latency on stimulus evaluation processes
12. P300 delay and attenuation in schizophrenia: Reversal by neuroleptic medication
13. P300: A state and a trait marker in schizophrenia
14. P300 subcomponent abnormalities in schizophrenia: II Longitudinal stability and relationship to symptom change
15. A review of magnetic resonance imaging studies of brain abnormalities in schizophrenia
16. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients
17. Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia
18. Trait and state aspects of P300 amplitude reduction in schizophrenia: A retrospective longitudinal study
19. Comparative assessment of saccadic eye movements, psychomotor and cognitive performance in schizophrenics, their first-degree relatives and control subjects
20. Abnormalities in late positive components of event-related potentials may reflect a genetic predisposition to schizophrenia
21. Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees
22. Alteration of event-related potentials in siblings discordant for schizophrenia
23. Genetic influence on auditory information processing in schizophrenia
24. Individual differences in P300 amplitude: A genetic study in adolescent twins
25. Impaired attention, genetics, and the pathophysiology of schizophrenia
26. Increased rate of P300 latency prolongation with age in schizophrenia. Electrophysiological evidence for a neurodegenerative process
27. Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia
28. P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms
29. Trait and state aspects of auditory P300 amplitude reduction in schizophrenia: A longitudinal study
30. P300 amplitude is related to clinical state in severely and moderately ill patients with schizophrenia
31. The relation between asymmetry and amplitude of the P300 field in schizophrenia
32. Are event-related potential abnormalities in schizophrenics trait or state dependent?
33. ERPs in schizophrenia: Effects of antipsychotic medication
34. P300 in schizophrenia: State or trait marker?
35. Effects of clozapine on auditory event-related potentials in schizophrenia
36. The effect of clozapine therapy on psychometric and event-related potentials (ERP) measures of cognitive dysfunction in schizophrenia
37. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients
38. The effects of clozapine and haloperidol on memory functioning in treatment refractory schizophrenics
39. Auditory event-related potentials and clinical scores in unmedicated schizophrenic patients
40. Left temporal lobe dysfunction in schizophrenia
41. First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe
42. Auditory P300 topography and neuropsychological test performance: Evidence for left hemispheric dysfunction in schizophrenia
43. Identification of neural circuits underlying P300 abnormalities in schizophrenia
44. Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia
45. Neurology of language
46. Topographic abnormalities of P300 in schizophrenic personality disorder
47. A controlled study of temporal lobe structure volumes and P300 responses in schizophrenic patients with persistent auditory hallucinations
48. Disordered functional connectivity in schizophrenia
49. Reduced auditory P300 amplitude, medial temporal volume reduction and psychopathology in schizophrenia
50. Opposite patterns of P300 asymmetry in schizophrenia are syndrome related
51. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment
52. Functional imaging of the brain in psychiatry. Mapping of EEG and evoked potentials
53. Left literalized P300 amplitude deficit in schizophrenic patients depends on pitch disparity
54. P300 topography differs in schizophrenia and manic psychosis
55. P300 topographic asymmetries are present in unmedicated schizophrenics
56. Reversed temporal region asymmetries of P300 topography in left- and right-handed schizophrenic subjects
57. P300 reduction and prolongation with illness duration in schizophrenia
58. Progressive brain volume changes and the clinical course of schizophrenia: A longitudinal magnetic resonance imaging study
59. P300 amplitude as a possible correlate of frontal degeneration in schizophrenia
60. Neurodevelopmental schizophrenia: The rediscovery of dementia praecox
61. Posterior superior temporal gyms in schizophrenia: Grey matter changes and clinical correlates
62. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia
63. Schizophrenia: The fundamental questions
64. Programmed cell death: Implications for neuropsychiatric disorders
65. Augmenting mental chronometry: The P300 as a measure of stimulus evaluation time
66. P300 in clinical application: Meaning, method, and measuring
67. Meta-analysis of P300 normative aging studies
68. Clinical utility of long latency "cognitive" event-related potentials (P3): The pros